Device Trial Radar · NCT07208604
Quantitative Refractive Crosslinking in Adults and Presbyopia-Aged Patients in the Philippines
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Oct 11, 2025
Primary completion
May 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- TECLens, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 6, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 25 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if the TECLens on-eye corneal crosslinking system can safely reduce refractive error (nearsightedness or farsightedness) in adults aged 25 to 75, including people who have reached the age when reading glasses are usually needed (presbyopia). The main questions it aims to answer are: Is the treatment safe for the cornea, including the cells that keep it clear? Does the treated eye's prescription change as planned, reaching within 0.75 diopters of the target 3 months after treatment? Participants will have one eye treated once with riboflavin (vitamin B2) eye drops and low-energy ultraviolet light delivered through a special contact lens. They will then return for eye exams 1 day, 1 week, and 1, 2, 3 and 6 months after treatment.
Conditions
- Presbyopia
- Refractive Errors
- Myopia
- Hyperopia
Interventions
TECLens CXLens Crosslinking SystemDevice
Investigational corneal crosslinking system that uses riboflavin and ultraviolet light, delivered through a scleral contact lens platform, to change the shape and refractive power of the cornea according to a treatment plan personalized for each eye.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Treated Eyes With Manifest Refraction Within 0.75 D of the Planned Target RefractionTime frame: 3 months after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asian Eye Institute
Makati City, National Capital Region, Philippines · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.